Moreover, the immunohistochemistry results suggested that the ECM components COL2A and aggrecan were markedly diminished, whereas the expressions of MMP13 were higher in the HCD group than in the control and atorvastatin groups. This evidence concerns the gene ACAN and heavy chain disease.